Cargando…
Neither ACEIs nor ARBs are associated with respiratory distress or mortality in COVID-19 results of a prospective study on a hospital-based cohort
Considerable concern has emerged for the potential harm in the use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor inhibitors (ARBs) in COVID-19 patients, given that ACEIs and ARBs may increase the expression of ACE2 receptors that represent the way for coronavirus 2 to...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508677/ https://www.ncbi.nlm.nih.gov/pubmed/32965603 http://dx.doi.org/10.1007/s11739-020-02500-2 |
_version_ | 1783585460847640576 |
---|---|
author | Anzola, Gian Paolo Bartolaminelli, Clara Gregorini, Gina Alessandra Coazzoli, Chiara Gatti, Francesca Mora, Alessandra Charalampakis, Dimitrios Palmigiano, Andrea De Simone, Michele Comini, Alice Dellaglio, Erica Cassetti, Salvatore Chiesa, Maurizio Spedini, Francesca d’Ottavi, Patrizia Savio, Maria Cristina |
author_facet | Anzola, Gian Paolo Bartolaminelli, Clara Gregorini, Gina Alessandra Coazzoli, Chiara Gatti, Francesca Mora, Alessandra Charalampakis, Dimitrios Palmigiano, Andrea De Simone, Michele Comini, Alice Dellaglio, Erica Cassetti, Salvatore Chiesa, Maurizio Spedini, Francesca d’Ottavi, Patrizia Savio, Maria Cristina |
author_sort | Anzola, Gian Paolo |
collection | PubMed |
description | Considerable concern has emerged for the potential harm in the use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor inhibitors (ARBs) in COVID-19 patients, given that ACEIs and ARBs may increase the expression of ACE2 receptors that represent the way for coronavirus 2 to entry into the cell and cause severe acute respiratory syndrome. Assess the effect of ACEI/ARBs on outcome in COVID-19 patients. Hospital-based prospective study. A total of 431 patients consecutively presenting at the Emergency Department and found to be affected by COVID-19 were assessed. Relevant clinical and laboratory variables were recorded, focusing on the type of current anti hypertensive treatment. Outcome variables were NO, MILD, SEVERE respiratory distress (RD) operationally defined and DEATH. Hypertension was the single most frequent comorbidity (221/431 = 51%). Distribution of antihypertensive treatment was: ACEIs 77/221 (35%), ARBs 63/221 (28%), OTHER than ACEIs or ARBs 64/221 (29%). In 17/221 (8%) antihypertensive medication was unknown. The proportion of patients taking ACEIs, ARBs or OTHERs who developed MILD or SEVERE RD was 43/77 (56%), 33/53 (52%), 39/64 (61%) and 19/77 (25%), 16/63 (25%) and 16/64 (25%), respectively, with no statistical difference between groups. Despite producing a RR for SEVERE RD of 2.59 (95% CI 1.93–3.49), hypertension was no longer significant in a logistic regression analysis that identified age, CRP and creatinine as the sole independent predictors of SEVERE RD and DEATH. ACEIs and ARBs do not promote a more severe outcome of COVID-19. There is no reason why they should be withheld in affected patients. |
format | Online Article Text |
id | pubmed-7508677 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-75086772020-09-23 Neither ACEIs nor ARBs are associated with respiratory distress or mortality in COVID-19 results of a prospective study on a hospital-based cohort Anzola, Gian Paolo Bartolaminelli, Clara Gregorini, Gina Alessandra Coazzoli, Chiara Gatti, Francesca Mora, Alessandra Charalampakis, Dimitrios Palmigiano, Andrea De Simone, Michele Comini, Alice Dellaglio, Erica Cassetti, Salvatore Chiesa, Maurizio Spedini, Francesca d’Ottavi, Patrizia Savio, Maria Cristina Intern Emerg Med Im - Original Considerable concern has emerged for the potential harm in the use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor inhibitors (ARBs) in COVID-19 patients, given that ACEIs and ARBs may increase the expression of ACE2 receptors that represent the way for coronavirus 2 to entry into the cell and cause severe acute respiratory syndrome. Assess the effect of ACEI/ARBs on outcome in COVID-19 patients. Hospital-based prospective study. A total of 431 patients consecutively presenting at the Emergency Department and found to be affected by COVID-19 were assessed. Relevant clinical and laboratory variables were recorded, focusing on the type of current anti hypertensive treatment. Outcome variables were NO, MILD, SEVERE respiratory distress (RD) operationally defined and DEATH. Hypertension was the single most frequent comorbidity (221/431 = 51%). Distribution of antihypertensive treatment was: ACEIs 77/221 (35%), ARBs 63/221 (28%), OTHER than ACEIs or ARBs 64/221 (29%). In 17/221 (8%) antihypertensive medication was unknown. The proportion of patients taking ACEIs, ARBs or OTHERs who developed MILD or SEVERE RD was 43/77 (56%), 33/53 (52%), 39/64 (61%) and 19/77 (25%), 16/63 (25%) and 16/64 (25%), respectively, with no statistical difference between groups. Despite producing a RR for SEVERE RD of 2.59 (95% CI 1.93–3.49), hypertension was no longer significant in a logistic regression analysis that identified age, CRP and creatinine as the sole independent predictors of SEVERE RD and DEATH. ACEIs and ARBs do not promote a more severe outcome of COVID-19. There is no reason why they should be withheld in affected patients. Springer International Publishing 2020-09-23 2020 /pmc/articles/PMC7508677/ /pubmed/32965603 http://dx.doi.org/10.1007/s11739-020-02500-2 Text en © Società Italiana di Medicina Interna (SIMI) 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Im - Original Anzola, Gian Paolo Bartolaminelli, Clara Gregorini, Gina Alessandra Coazzoli, Chiara Gatti, Francesca Mora, Alessandra Charalampakis, Dimitrios Palmigiano, Andrea De Simone, Michele Comini, Alice Dellaglio, Erica Cassetti, Salvatore Chiesa, Maurizio Spedini, Francesca d’Ottavi, Patrizia Savio, Maria Cristina Neither ACEIs nor ARBs are associated with respiratory distress or mortality in COVID-19 results of a prospective study on a hospital-based cohort |
title | Neither ACEIs nor ARBs are associated with respiratory distress or mortality in COVID-19 results of a prospective study on a hospital-based cohort |
title_full | Neither ACEIs nor ARBs are associated with respiratory distress or mortality in COVID-19 results of a prospective study on a hospital-based cohort |
title_fullStr | Neither ACEIs nor ARBs are associated with respiratory distress or mortality in COVID-19 results of a prospective study on a hospital-based cohort |
title_full_unstemmed | Neither ACEIs nor ARBs are associated with respiratory distress or mortality in COVID-19 results of a prospective study on a hospital-based cohort |
title_short | Neither ACEIs nor ARBs are associated with respiratory distress or mortality in COVID-19 results of a prospective study on a hospital-based cohort |
title_sort | neither aceis nor arbs are associated with respiratory distress or mortality in covid-19 results of a prospective study on a hospital-based cohort |
topic | Im - Original |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508677/ https://www.ncbi.nlm.nih.gov/pubmed/32965603 http://dx.doi.org/10.1007/s11739-020-02500-2 |
work_keys_str_mv | AT anzolagianpaolo neitheraceisnorarbsareassociatedwithrespiratorydistressormortalityincovid19resultsofaprospectivestudyonahospitalbasedcohort AT bartolaminelliclara neitheraceisnorarbsareassociatedwithrespiratorydistressormortalityincovid19resultsofaprospectivestudyonahospitalbasedcohort AT gregoriniginaalessandra neitheraceisnorarbsareassociatedwithrespiratorydistressormortalityincovid19resultsofaprospectivestudyonahospitalbasedcohort AT coazzolichiara neitheraceisnorarbsareassociatedwithrespiratorydistressormortalityincovid19resultsofaprospectivestudyonahospitalbasedcohort AT gattifrancesca neitheraceisnorarbsareassociatedwithrespiratorydistressormortalityincovid19resultsofaprospectivestudyonahospitalbasedcohort AT moraalessandra neitheraceisnorarbsareassociatedwithrespiratorydistressormortalityincovid19resultsofaprospectivestudyonahospitalbasedcohort AT charalampakisdimitrios neitheraceisnorarbsareassociatedwithrespiratorydistressormortalityincovid19resultsofaprospectivestudyonahospitalbasedcohort AT palmigianoandrea neitheraceisnorarbsareassociatedwithrespiratorydistressormortalityincovid19resultsofaprospectivestudyonahospitalbasedcohort AT desimonemichele neitheraceisnorarbsareassociatedwithrespiratorydistressormortalityincovid19resultsofaprospectivestudyonahospitalbasedcohort AT cominialice neitheraceisnorarbsareassociatedwithrespiratorydistressormortalityincovid19resultsofaprospectivestudyonahospitalbasedcohort AT dellaglioerica neitheraceisnorarbsareassociatedwithrespiratorydistressormortalityincovid19resultsofaprospectivestudyonahospitalbasedcohort AT cassettisalvatore neitheraceisnorarbsareassociatedwithrespiratorydistressormortalityincovid19resultsofaprospectivestudyonahospitalbasedcohort AT chiesamaurizio neitheraceisnorarbsareassociatedwithrespiratorydistressormortalityincovid19resultsofaprospectivestudyonahospitalbasedcohort AT spedinifrancesca neitheraceisnorarbsareassociatedwithrespiratorydistressormortalityincovid19resultsofaprospectivestudyonahospitalbasedcohort AT dottavipatrizia neitheraceisnorarbsareassociatedwithrespiratorydistressormortalityincovid19resultsofaprospectivestudyonahospitalbasedcohort AT saviomariacristina neitheraceisnorarbsareassociatedwithrespiratorydistressormortalityincovid19resultsofaprospectivestudyonahospitalbasedcohort |